Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease
Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Subjects have a type of lymph gland cancer called Hodgkin or non-Hodgkin Lymphoma, which has
come back or not gone away after treatment, including the best treatment we know for relapsed
Lymphoma. We are asking subjects to volunteer to be in a research study using Epstein Barr
virus (EBV) specific cytotoxic T lymphocytes, a new experimental therapy. This therapy has
never been used in patients with Hodgkin disease or this type of non-Hodgkin Lymphoma but it
has been used successfully in children with other types of blood cancer caused by EBV after
bone marrow transplantation.
Some patients with Hodgkin disease or non-Hodgkin Lymphoma show evidence of infection with
the virus that causes infectious mononucleosis Epstein Barr virus (EBV) before or at the time
of their diagnosis of Lymphoma. EBV is often found in the cancer cells suggesting that it may
play a role in causing Lymphoma. The cancer cells infected by EBV are very clever because
they are able to hide from the body's immune system and escape destruction. We want to see if
we can grow special white blood cells, called T cells, that have been trained to kill EBV
infected cells and give them back to subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Center for Cell and Gene Therapy, Baylor College of Medicine Texas Children's Hospital The Methodist Hospital Research Institute The Methodist Hospital System